FDA advisors support approval for Ferring's intestinal infection medicine
All signs indicate that Ferring Pharmaceuticals is on the cusp of being market authorized for its biologic candidate against C. difficile infection.
by ulrich quistgaard, translated by daniel pedersen
The US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has decided in a vote to back the approval of Ferring Pharmaceutical’s drug candidate, RBX2660, the Swiss company announces in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ferring VP steps down as chair of API manufacturer
For subscribers
.jpg&w=384&q=75)
